These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3285526)

  • 1. Clinical significance of anti-Yt(b). Report of a case using a 51chromium red cell survival study.
    Levy GJ; Selset G; McQuiston D; Nance SJ; Garratty G; Smith LE; Goldfinger D
    Transfusion; 1988; 28(3):265-7. PubMed ID: 3285526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 51Chromium survival of Yt(a+) red cells as a determinant of the in vivo significance of anti-Yta.
    Davey RJ; Simpkins SS
    Transfusion; 1981; 21(6):702-5. PubMed ID: 7314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell transfusion in patients with anti-Yt
    Wong SM; Cawthorne T; Dennington PM; Hong FS
    Transfusion; 2021 Feb; 61(2):379-384. PubMed ID: 33410173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Jka, -C, and -E in a single patient, initially demonstrable only by the manual hexadimethrine bromide (Polybrene) test, with incompatibilities confirmed by 51Cr-labeled red cell studies.
    Maynard BA; Smith DS; Farrar RP; Kraetsch RE; Chaplin H
    Transfusion; 1988; 28(4):302-6. PubMed ID: 3133842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically significant allo-anti-I in an I-negative patient with massive hemorrhage.
    Chaplin H; Hunter VL; Malecek AC; Kilzer P; Rosche ME
    Transfusion; 1986; 26(1):57-61. PubMed ID: 3946005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some observations on the Inb antigen and evidence that anti-Inb causes accelerated destruction of radiolabeled red cells.
    Ferguson DJ; Gaal HD
    Transfusion; 1988; 28(5):479-82. PubMed ID: 3420678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An example of anti-Yta demonstrating a change in its clinical significance.
    AuBuchon JP; Brightman A; Anderson HJ; Kim B
    Vox Sang; 1988; 55(3):171-5. PubMed ID: 3238951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of transfused red cell survival using an enzyme-linked antiglobulin test.
    Kickler TS; Smith B; Bell W; Drew H; Baldwin M; Ness PM
    Transfusion; 1985; 25(5):401-5. PubMed ID: 4049483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid in vivo destruction of Yt(a+) erythrocytes in a recipient with anti-Yta.
    Ballas SK; Sherwood WC
    Transfusion; 1977; 17(1):65-6. PubMed ID: 841677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the clinical significance of anti-Cra and anti-M in a chronically transfused sickle cell patient.
    Leatherbarrow MB; Ellisor SS; Collins PA; Douglas DK; Eckrich RJ; Esty SS; Baldwin ML; Ness PM
    Immunohematology; 1988; 4(4):71-4. PubMed ID: 15945939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxygen-dependent circulation of sickle erythrocytes.
    Castro O; Osbaldiston GW; Aponte L; Roth R; Orlin J; Finch SC
    J Lab Clin Med; 1976 Nov; 88(5):732-44. PubMed ID: 988104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful transfusion of antigen positive blood to alloimmunised patients using a monocyte monolayer assay.
    Noumsi GT; Billingsley KL; Moulds JM
    Transfus Med; 2015 Apr; 25(2):92-100. PubMed ID: 25828731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of Er(a+) red cells in a patient with allo-anti-Era.
    Thompson HW; Skradski KJ; Thoreson JR; Polesky HF
    Transfusion; 1985; 25(2):140-1. PubMed ID: 3984007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal survival of Rh0 (D) negative, LW (a+) red cells in a patient with allo-anti LWa.
    Cummings E; Pisciotto P; Roth G
    Vox Sang; 1984; 46(5):286-90. PubMed ID: 6428046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A second example of anti-Yta with rapid in vivo destruction of Yt(a plus) red cells.
    Göbel U; Drescher KH; Pöttgen W; Lehr HJ
    Vox Sang; 1974; 27(2):171-5. PubMed ID: 4850290
    [No Abstract]   [Full Text] [Related]  

  • 16. Survival Time of Cross-Match Incompatible Red Blood Cells in Adult Horses.
    Tomlinson JE; Taberner E; Boston RC; Owens SD; Nolen-Walston RD
    J Vet Intern Med; 2015; 29(6):1683-8. PubMed ID: 26478135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of antibody following 51chromium survival studies.
    Esty SS; Wahl T; Zawisza J; Mallory D; Davey RJ
    Immunohematology; 1987; 3(1):6-8. PubMed ID: 15945886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods.
    Luten M; Roerdinkholder-Stoelwinder B; Schaap NP; de Grip WJ; Bos HJ; Bosman GJ
    Transfusion; 2008 Jul; 48(7):1478-85. PubMed ID: 18482180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-AnWj causing acute hemolytic transfusion reactions in a patient with aplastic anemia.
    Xu Z; Duffett L; Tokessy M; Cote J; Goldman M; Saidenberg E
    Transfusion; 2012 Jul; 52(7):1476-81. PubMed ID: 22233405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.
    Cancelas JA; Gottschall JL; Rugg N; Graminske S; Schott MA; North A; Huang N; Mufti N; Erickson A; Rico S; Corash L
    Vox Sang; 2017 Apr; 112(3):210-218. PubMed ID: 28220519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.